Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
Prospective, Single-arm, Multicentre Study, Using a Historical Control, to Evaluate the Efficacy/Safety and Population Pharmacokinetics of Benznidazole in Children With Chronic Indeterminate Chagas Disease
INTERVENTIONAL
Inicio: 19 de sept de 2019
ID: NCT04024163
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants
INTERVENTIONAL
Inicio: 25 de ago de 2025
ID: NCT07160244
Desconocido
ClinicalTrials.gov
Multifactorial Approach to Dementia. Multicentric Study
OBSERVATIONAL
Inicio: 20 de may de 2023
ID: NCT05923307
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-2)
INTERVENTIONAL
Inicio: 24 de ago de 2021
ID: NCT04846881
Terminado
Fase 2
ClinicalTrials.gov
NASH EXploratory Single and COmbination Treatment (NEXSCOT): An Open Label, Multicenter, Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Various Single and Combination Treatments in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Who Manifest a Non-alcoholic Steatohepatitis (NASH)-Like Biomarker Phenotype
INTERVENTIONAL
Inicio: 4 de jun de 2020
ID: NCT04147195
Completado
Fase 3
ClinicalTrials.gov
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
INTERVENTIONAL
Inicio: 1 de oct de 2018
ID: NCT03631706
Terminado
Fase 3
ClinicalTrials.gov
A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). "PR" is Synonymous With "ER" and is Interchangeable.
INTERVENTIONAL
Inicio: 1 de jun de 2007
ID: NCT00505414
Completado
Fase 2
ClinicalTrials.gov
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma
INTERVENTIONAL
Inicio: 1 de dic de 2007
ID: NCT00600171
Completado
Fase 3
ClinicalTrials.gov
Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00631371
Desconocido
ClinicalTrials.gov
Adherence to Low Tidal Volume in the Transition to Spontaneous Ventilation Mode in Patients With Acute Respiratory Failure in ICUs in Latin America
OBSERVATIONAL
Inicio: 12 de jun de 2023
ID: NCT06042036
Completado
Fase 3
ClinicalTrials.gov
A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.
INTERVENTIONAL
Inicio: 1 de mar de 2008
ID: NCT00660907
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
INTERVENTIONAL
Inicio: 8 de mar de 2022
ID: NCT05275400
Completado
Fase 3
ClinicalTrials.gov
A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD
INTERVENTIONAL
Inicio: 1 de mar de 2009
ID: NCT00845728
Reclutando
ClinicalTrials.gov
Establishment and Exploitation of a European-Latin American Research Consortium Towards Eradication of Preventable Gallbladder Cancer - EULAT Eradicate GBC
OBSERVATIONAL
Inicio: 1 de dic de 2019
ID: NCT06192719
Completado
ClinicalTrials.gov
Efficacy of Virtual Reality Exercises Using Wii Gaming Technology in STroke Rehabilitation: A Multicentre Randomized Clinical Trial (EVREST Multicentre)
INTERVENTIONAL
Inicio: 1 de jul de 2011
ID: NCT01406912
Terminado
Fase 3
ClinicalTrials.gov
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor
INTERVENTIONAL
Inicio: 23 de dic de 2022
ID: NCT05605093
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney Disease
INTERVENTIONAL
Inicio: 21 de sept de 2021
ID: NCT05047263
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
INTERVENTIONAL
Inicio: 22 de dic de 2025
ID: NCT07128199
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
INTERVENTIONAL
Inicio: 20 de jul de 2022
ID: NCT05382299
Completado
Fase 3
ClinicalTrials.gov
A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d.) and Open Label Tiotropium (18 µg o.d.) as Active Controls
INTERVENTIONAL
Inicio: 1 de abr de 2007
ID: NCT00463567
Anterior
1
...
421
422
423
...
434
Siguiente
Filtros